BioPharma Dive’s Post

Exciting News Alert! We're thrilled to announce that EQUULUS has been featured in Psychedelic Alpha! Led by Robert Discordia, a drug development journeyman from Bristol Myers Squibb and former executive at Corbus Pharmaceuticals and CaaMTech, EQUULUS aims to revolutionize psychedelic drug development. Our lead candidate, EQL-101, a non-hallucinogenic and non-cardiotoxic ibogaine analog, targets Substance Use Disorders (SUDs), including Opioid Use Disorder (OUD). But that's not all! Our second program, EQL-201, targets nicotine use disorder, focusing on overweight and obese individuals, a population linked to worse health outcomes. With proprietary differentiators in our candidates, partnerships with RTI International and Küleon Bioscience, and a transdiagnostic approach, EQUULUS is set to make waves in the neuroscience landscape. #psychedelic #ibogaine #opioidusedisorder #addiction #nicotineusedisorder

*🔴Endoxifen in Bipolar Disprder🔴* ⏩ "Endoxifen, a Protein Kinase C Inhibitor, is approved in India for Manic Episodes in Bipolar Disorder." ⏩"It is aggressively marketed by pharmaceutical companies, and its use has widened to other Bipolar Disorders and substance use." ❓❓*Is there strong evidence to support the use of Endoxifen in Bipolar Disorder?* 👉"We conducted a systematic review of existing literature on the use of Endoxifen in Bipolar Disorder, and the findings are now published in Human Psychopharmacology Clinical and Experimental. 👉"We could only find a few case reports and two Pharma-sponsored trials." 👉” Even though some studies show that Endoxifen can reduce manic symptoms, its efficacy in other conditions as well as long-term use is yet to be established." 👉"Additionally, data on the long-term safety of Endoxifen is limited." 🔴"We found some concerns with the published case reports and clinical trials, which are discussed in the article." 👉"To summarize, even though existing evidence shows that Endoxifen can reduce manic symptoms, there is a need for larger, well-controlled trials to establish its efficacy and safety." ✅✅"Practitioners should be aware of the quality and strength of evidence before considering prescribing Endoxifen." Please find the full findings here http://surl.li/thxhy Rashmi Vishwanath Samir Kumar Praharaj

Client Feature! Check out Psychedelic Alpha's newest bulletin discussing EQUULUS Therapeutics!

"Anti-glaucoma medications" Important notes: - The "systemic" absorption may occur with the eye drops, leading to serious systemic side effects, so caution MUST be considered especially with elderly patients with chronic diseases - "Rho kinase inhibitor" is considered the newest anti-glaucoma agent, Netarsudil (Rhopressa®) is the first agent in this class approved by FDA in 2017. Due to lack long-term experience, it is not considered as a first or second line therapy (first-line is prostaglandin analogs & second-line is beta-blockers) and be used in combination with other treatments - Alpha 2 agonists can cross the "blood brain barrier" leading to serious side effects like hypotension (caution MUST considered)  - Echothiophate (cholinesterase inhibitors) is another anti-glaucoma agent, which used only for specific conditions, so it is not widely used References: - Katzung's basic & clinical pharmacology, 16th edition  - The APhA complete review for pharmacy, 13th edition  - Lippincott pharmacology, 8th edition - BNF 86

We love BioPharma Dive's round up of FDA decisions to watch in #Q3. We're keeping an eye on Bristol Myers Squibb and Karuna Therapeutics' #schizophrenia drug, Lykos Therapeutics' #PTSD therapy, Gilead Sciences' liver drug for #primarybiliarycholangitis, Ascendis Pharma' #rare endocrine condition #hypoparathyroidism, and Adaptimmune's cell therapy drug for synovial sarcoma. Read more here: https://lnkd.in/gJDP8sCE

$MIRA Exciting News from MIRA Pharmaceuticals! 🚀 We are thrilled to share a recent update on our research report from Zacks Investment Research that highlights more positive test results for our innovative drug candidates. These findings are a significant step forward in our mission to develop groundbreaking treatments for neurological and neuropsychiatric disorders. Key Highlights: Our novel compounds, MIRA-55 and Ketamir-2, are showing promising results in preclinical trials. These advancements underscore our commitment to improving patient outcomes with safer, more effective therapies. Please note: The results mentioned are from preclinical studies, and Ketamir-2 & Mira-55 is still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 has not been approved by the FDA, and further studies are necessary to determine its potential for human use. 👉 Read the full report here https://lnkd.in/ebbM3f6V #Innovation #Research #Healthcare #Neurology #MentalHealth #Pharmaceuticals #ClinicalResearch #DrugDevelopment #MIRA #Depression #Suicide #Neuropathicpain #PTSD #FDA

$MIRA Exciting News from MIRA Pharmaceuticals! 🚀 We are thrilled to share a recent update on our research report from Zacks Investment Research that highlights more positive test results for our innovative drug candidates. These findings are a significant step forward in our mission to develop groundbreaking treatments for neurological and neuropsychiatric disorders. Key Highlights: Our novel compounds, MIRA-55 and Ketamir-2, are showing promising results in preclinical trials. These advancements underscore our commitment to improving patient outcomes with safer, more effective therapies. Please note: The results mentioned are from preclinical studies, and Ketamir-2 & Mira-55 are still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 has not been approved by the FDA, and further studies are necessary to determine its potential for human use. 👉 Read the full report here https://lnkd.in/ebbM3f6V #Innovation #Research #Healthcare #Neurology #MentalHealth #Pharmaceuticals #ClinicalResearch #DrugDevelopment #MIRA #Depression #Suicide #Neuropathicpain #PTSD #FDA

𝐅𝐃𝐀 𝐧𝐨𝐯𝐞𝐥 𝐝𝐫𝐮𝐠 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐢𝐧 2023 With a significant increase of 48% compared to the previous year, in 2023 the #FDA approved a total of 55 novel drugs! Rare Diseases made most of it with more than half (28 of 55, or 51%) of the novel drugs, approved to prevent, diagnose or treat a #rare #disease or condition, for which they received an orphan-drug designation. The therapeutic areas distribution is as follows: Hematology      21% Oncology            15% Neurology          15% Genetics             9% Infectious Diseases 6% Dermatology     6% Endocrinology  6% Gastroenterology 6% Ophthalmology 6% Nephrology       4% Psychiatry          4% Cardiology          2% Immunology     2% Sources: https://lnkd.in/eT86V5d4 https://lnkd.in/dReR5cVN #healthcare #clinicaltrials #drugdevelopment #RD #health #CRO #clinicalresearch